Eyebright Medical(SH:688050)2023-04-18 16:00Financial Performance - Net profit attributable to shareholders of the listed company was ¥78,398,180.86, reflecting a growth of 33.58% year-on-year [23]. - Operating income for the first quarter was ¥189,790,145.25, representing a year-on-year increase of 44.55% [23]. - Basic earnings per share were ¥0.75, an increase of 33.93% compared to the same period last year [23]. - Net profit attributable to shareholders increased by 33.58%, primarily due to revenue growth, although the growth rate was lower than that of operating revenue due to increased operating costs and reduced government subsidies compared to the previous year [27]. - Net profit attributable to shareholders after deducting non-recurring gains and losses rose by 43.88%, aligning closely with the growth rate of operating revenue [27]. - Net profit for Q1 2023 was ¥76,436,896.80, compared to ¥56,973,417.09 in Q1 2022, reflecting a growth of approximately 34.3% [37]. - Basic earnings per share for Q1 2023 were ¥0.75, an increase from ¥0.56 in Q1 2022 [38]. Revenue and Costs - Operating revenue increased by 44.55%, driven by the rapid recovery in sales of the "Punoming" series artificial lenses and "Punotong" corneal shaping lenses, along with a significant contribution of over 11% from other optical products [27]. - Total operating revenue for Q1 2023 reached ¥189,790,145.25, a significant increase from ¥131,293,097.39 in Q1 2022, representing a growth of approximately 44.4% [36]. - Total operating costs for Q1 2023 were ¥105,685,952.34, up from ¥64,270,661.60 in Q1 2022, indicating an increase of about 64.5% [36]. Research and Development - Research and development expenses totaled ¥25,064,163.49, which is 68.89% higher than the previous year, accounting for 13.21% of operating income [23]. - Total R&D investment increased by 68.89%, reflecting the company's efforts to enhance competitiveness and sustainable development capabilities [30]. - The company's research and development expenses for Q1 2023 were ¥20,281,491.30, up from ¥12,616,211.99 in Q1 2022, indicating an increase of approximately 60.5% [36]. Cash Flow and Assets - The net cash flow from operating activities was ¥27,162,135.98, showing a decrease of 33.54% compared to the previous year [23]. - Cash received from sales of goods and services in Q1 2023 amounted to ¥181,511,092.41, compared to ¥120,725,489.62 in Q1 2022, marking a growth of about 50.4% [38]. - The total assets at the end of the reporting period reached ¥2,320,453,439.44, an increase of 3.39% compared to the end of the previous year [6]. - Cash inflow from investment activities totaled CNY 515,907,634.08, significantly up from CNY 181,259,067.00, indicating a strong recovery in investment returns [40]. - The total cash and cash equivalents at the end of the period stood at CNY 298,750,468.63, down from CNY 472,871,517.38, reflecting a decrease of 36.7% [41]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,519, with the largest shareholder holding 12.93% of the shares [10]. - The total equity attributable to shareholders of the listed company was ¥1,942,598,869.87, up 4.43% from the previous year [6]. - The company reported a total of CNY 1,942,598,869.87 in equity attributable to shareholders, an increase from CNY 1,860,185,637.42 [46]. Regulatory and Market Activities - The company received regulatory approval for new products, including pre-formed aspheric intraocular lenses and a physiological saline nasal spray [12]. - The company plans to accelerate the promotion of new products and brand marketing activities to further drive revenue growth in the future [27].